Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.

被引：3
|
作者：
Omlin, Aurelius Gabriel
Daugaard, Gedske
Peer, Avivit
Reichegger, Hermann
Neumann, Avivit
Rosenbaum, Eli
Desax, Marie-Claire
Neiman, Victoria
Petersen, Peter Meidahl
Mueller, Joachim
Cathomas, Richard
Gottfried, Maya
Sarid, David
Gez, Eli
Mermershtain, Wilmosh
Rouvinov, Keren
Mortensen, Jann
Gillessen, Silke
Keizman, Daniel
机构：
[1] Kantonsspital St Gallen, St Gallen, Switzerland
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Rambam Hlth Care Campus, Haifa, Israel
[4] Cantonal Hosp St Gallen, St Gallen, Switzerland
[5] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[6] Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel
[7] Rabin Med Ctr, Davidoff Canc Ctr, Petach-Tikva, Israel
[8] Rigshosp, Dept Oncol, Copenhagen, Denmark
[9] Kantonsspital Chur, Chur, Switzerland
[10] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[11] Ichilov Hosp, Sourasky Med Ctr, Tel Aviv, Israel
[12] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[13] Soroka Med Ctr, Beer Sheva, Israel
[14] Rigshosp, Nucl Med & PET, Dept Clin Physiol, Copenhagen, Denmark
[15] Tel Aviv Univ, Sackler Sch Med, Div Oncol, Meir Med Ctr,Genitourinary Oncol Serv, Kefar Sava, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5057
引用
收藏
页数：3
相关论文
共 50 条
  • [41] 3-year safety yellow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Parker, Chris
    Vogelzang, Nicholas J.
    Salter, A. Oliver
    Coleman, Robert E.
    Fang, Fang
    Skjorestad, Irene
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [42] Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Parker, C.
    Heinrich, D.
    Bottomley, D.
    Hoskin, P.
    Franzen, L.
    Solberg, A.
    Pawar, V.
    Reuning-Scherer, J.
    O'Bryan-Tear, C. G.
    Nilsson, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S689 - S689
  • [43] Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial.
    Connell, Brendan James
    Folefac, Edmund
    Hwang, Clara
    Lawlor, Christian
    Mathew, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [44] Combination Therapy With Radium-223 and Enzalutamide in Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 764 - 766
  • [45] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel (D) therapy in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S., I
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [46] Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer
    Shimada, Takafumi
    Izumi, Kouji
    Kano, Hiroshi
    Kadomoto, Suguru
    Makino, Tomoyuki
    Naito, Renato
    Iwamoto, Hiroaki
    Yaegashi, Hiroshi
    Kadono, Yoshifumi
    Mizokami, Atsushi
    ANTICANCER RESEARCH, 2022, 42 (02) : 1065 - 1071
  • [47] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
    Finkelstein, Steven E.
    Michalski, Jeff M.
    O'Sullivan, Joe M.
    Parker, Chris
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [48] Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer
    Saylor, Philip J.
    Otani, Keisuke
    Balza, Rene
    Ukleja, Jacob
    Pleskow, Haley
    Fisher, Rebecca
    Kusaka, Erika
    Otani, Yukako S.
    Badusi, Priscilla Oluwakemi
    Smith, Matthew R.
    Meneely, Erika
    Olivier, Kara
    Lowe, Alarice C.
    Toner, Mehmet
    Maheswaran, Shyamala
    Haber, Daniel A.
    Yeap, Beow Y.
    Lee, Richard J.
    Miyamoto, David T.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [49] Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
    Vogelzang, Nicholas J.
    Parker, Chris
    Nilsson, Sten
    Coleman, Robert Edward
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [50] Updated Analysis of Radium-223 Dichloride (Ra-223) Impact on Survival, Safety, and Skeletal-Related Events in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases From the Phase 3 ALSYMPCA Trial
    Wedel, S.
    Kranert, T. W.
    Chodacki, A.
    Staudacher, K.
    Garcia-Vargas, J.
    Parker, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S190 - S190
12345